COGENT BIOSCIENCES INC (COGT) — insider trading
Health Care · NASDAQ
COGENT BIOSCIENCES INC (COGT) has 22 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 22 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Ferrante Karen Jean | Director | Grant / award / vesting (derivative) | 759 | — | $0 | Form 4 |
| 2026-08-27 | Morris Arlene | Director | Option exercise / conversion (derivative) | 3,583 | — | $0 | Form 4 |
| 2026-08-27 | Morris Arlene | Director | Option exercise / conversion (derivative) | 41,927 | — | $0 | Form 4 |
| 2026-08-27 | Morris Arlene | Director | Open-market sale | 3,161 | $37.54 | $118.7K | Form 4 |
| 2026-08-27 | Morris Arlene | Director | Open-market sale | 42,349 | $37.09 | $1.57M | Form 4 |
| 2026-08-27 | Morris Arlene | Director | Option exercise / conversion | 3,583 | $2.52 | $9.0K | Form 4 |
| 2026-08-27 | Morris Arlene | Director | Option exercise / conversion | 41,927 | $5.64 | $236.5K | Form 4 |
| 2026-07-01 | Ferrante Karen Jean | Director | Grant / award / vesting (derivative) | 627 | — | $0 | Form 4 |
| 2026-06-09 | Ros Matthew | Director | Grant / award / vesting (derivative) | 17,901 | — | $0 | Form 4 |
| 2026-06-09 | Morris Arlene | Director | Grant / award / vesting (derivative) | 17,901 | — | $0 | Form 4 |
| 2026-06-09 | Shegog Todd | Director | Grant / award / vesting (derivative) | 17,901 | — | $0 | Form 4 |
| 2026-06-09 | CAIN CHRISTOPHER W. | Director | Grant / award / vesting (derivative) | 17,901 | — | $0 | Form 4 |
| 2026-06-09 | Ferrante Karen Jean | Director | Grant / award / vesting (derivative) | 17,901 | — | $0 | Form 4 |
| 2026-06-09 | Harwin Peter Evan | Director | Grant / award / vesting (derivative) | 17,901 | — | $0 | Form 4 |
| 2026-05-19 | Robbins Andrew R | Director, Officer (President and CEO) | Bona fide gift | 160,000 | — | $0 | Form 4 |
| 2026-05-19 | Robbins Andrew R | Director, Officer (President and CEO) | Bona fide gift | 160,000 | — | $0 | Form 4 |
| 2026-04-01 | Ferrante Karen Jean | Director | Grant / award / vesting (derivative) | 686 | — | $0 | Form 4 |
| 2026-03-31 | Fairmount Funds Management LLC | Director | Conversion of derivative (derivative) | 28,000 | — | $0 | Form 4 |
| 2026-03-31 | Fairmount Funds Management LLC | Director | Open-market sale | 7,000,000 | $34.66 | $242.62M | Form 4 |
| 2026-03-31 | Fairmount Funds Management LLC | Director | Conversion of derivative | 7,000,000 | — | — | Form 4 |
| 2026-01-22 | Fairmount Funds Management LLC | Director | Open-market sale | 3,500,000 | $36.40 | $127.40M | Form 4 |
| 2026-01-01 | Ferrante Karen Jean | Director | Grant / award / vesting (derivative) | 643 | — | $0 | Form 4 |
Ask the chat about COGT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: COGENT BIOSCIENCES INC (COGT).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.